Goldman Sachs’s LianBio American Depositary Shares LIAN Stock Holding History

Goldman Sachs’s Portfolio LIAN Stock Details LIAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,621	Closed	-$4.72K	–	6062
2024 Q1	$4.72K	Buy	+14,621	New	+$62.9K	﹤0.01%	5460
2022 Q4	–	Sell	-12,157	Closed	-$24K	–	6351
2022 Q3	$24K	Buy	+12,157	New	+$29.1K	﹤0.01%	5906
2022 Q2	–	Sell	-43,185	Closed	-$160K	–	6811
2022 Q1	$160K	Buy	+43,185	New	+$178K	﹤0.01%	5955

Other funds holding LIAN

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Goldman Sachs's LIAN Position: Q2 2024 in Review

Goldman Sachs sold out of LianBio American Depositary Shares (LIAN) in Q2 2024, closing a stake of 14,621 shares — an estimated $4.72K sold.

Goldman Sachs first reported a position in LIAN in Q1 2022 and held it in 3 quarters. The position peaked at $160K in Q1 2022. 2 funds tracked by Wall St. Rank hold LIAN as of Q2 2024.

Goldman Sachs reported no remaining LianBio American Depositary Shares position as of Q2 2024 after selling out during the quarter.
Goldman Sachs sold 14,621 LianBio American Depositary Shares shares in Q2 2024, an estimated $4.72K.
Goldman Sachs first reported a position in LianBio American Depositary Shares in Q1 2022 and held it in 3 quarters.
Goldman Sachs's LianBio American Depositary Shares position peaked at $160K in Q1 2022.
2 funds tracked by Wall St. Rank held LianBio American Depositary Shares as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.